Clinical trial · Interventional
Digital Rehabilitation With Wearable Monitors for Sequential Lung Cancer Resection
A Clinical Trial of Rehabilitation During Sequential Resection of Multiple Primary Non-Small Cell Lung Cancer Based on Wireless Wearable Mobile Monitoring Devices
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, open-label, parallel-group, 1:1 randomized controlled trial designed to evaluate whether a digital rehabilitation program integrated with wireless wearable continuous monitoring devices can shorten the time to functional recovery in patients with multiple primary non-small cell lung cancer (MPLC) who undergo sequential (two-stage) curative-intent resection. Eligible participants will be randomly assigned to either the intervention group or the control group. Both groups will receive standard enhanced recovery after surgery (ERAS) care. In addition, the intervention group will receive continuous vital sign monitoring (using a wearable patch during hospitalization and a wrist-worn device after discharge), personalized exercise prescriptions with daily step targets, and high-frequency electronic patient-reported outcome (ePRO) follow-up with threshold-triggered response. The control group will receive standard intermittent vital sign monitoring and conventional rehabilitation education. The primary endpoint is the time from the first surgery to attainment of functional recovery criteria sufficient for second-stage surgery readiness (assessed by a composite of step count recovery, functional interference score combined with 6-minute walk distance, or multidisciplinary team determination). Secondary endpoints include pulmonary function recovery (FEV1%, FVC%, DLCO% at 3 months), physical activity (daily steps, moderate-to-vigorous physical activity, 6-minute walk distance), symptom burden and quality of life (EORTC QLQ-C30/LC13, PROMIS), 30- and 90-day complication and readmission rates, second-surgery-related outcomes, adherence, safety, and healthcare resource utilization. A total of 222 participants (111 per group) will be enrolled. The study will be conducted at West China Hospital of Sichuan University from June 2026 to October 2027. The findings are expected to provide high-quality evidence on the clinical utility of wearable-integrated digital rehabilitation in the perioperative management of MPLC patients undergoing sequential resection.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
| Rehabilitation | — | UNRESOLVED | — |
| Thoracic Surgery | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Digital Pulmonary Rehabilitation Program | Behavioral | — | UNRESOLVED |
| Standard ERAS Perioperative and Rehabilitation Care | Other | — | UNRESOLVED |
| Wireless Wearable Vital Sign and Activity Monitor | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Digital Rehabilitation with Wearable Monitoring
- description
- Participants receive standard ERAS/ERATS perioperative care plus a wireless wearable mobile monitoring and digital rehabilitation program. This includes: (1) continuous vital sign monitoring via a wearable patch during hospitalization and a wrist-worn activity tracker after discharge; (2) personalized exercise prescriptions (aerobic, resistance, and inspiratory muscle training) with progressive step goals; (3) high-frequency electronic patient-reported outcome (ePRO) symptom surveillance; and (4) threshold-triggered graded responses (e.g., SpO₂ \<90%, persistent tachycardia, symptom escalation) prompting telephone follow-up, outpatient visit, or emergency care.
- interventionNames
- Device: Wireless Wearable Vital Sign and Activity Monitor
- Behavioral: Digital Pulmonary Rehabilitation Program
- type
- ACTIVE_COMPARATOR
- label
- Standard ERAS Perioperative Care
- description
- Participants receive standard perioperative care and conventional rehabilitation education according to institutional practice. This includes routine intermittent vital sign monitoring during hospitalization and standard follow-up visits. No continuous wearable monitoring or digital rehabilitation prescription is provided.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 and ≤85 years * Histopathologically confirmed primary non-small cell lung cancer (NSCLC) meeting diagnostic criteria for multiple primary lung cancer (MPLC, unilateral or bilateral multifocal lesions), scheduled for elective sequential (two-stage) curative-intent resection; the first-stage surgery (lobectomy or segmentectomy) has been performed or is planned within 7 days after enrollment, with the second-stage surgery planned within 12 weeks postoperatively * Planned discharge between postoperative day 2 and day 7, and judged by the investigator to be clinically stable and suitable for home-based/out-of-hospital rehabilitation * Able to operate a smartphone application and wearable devices independently or with caregiver assistance, with stable cellular/broadband network access * Eastern Cooperative Oncology Group (ECOG) performance status 0-2, and preoperatively assessed as able to tolerate routine rehabilitation training * Intact skin at the wearable device attachment sites, without severe skin diseases affecting device placement * Willing and able to provide written informed consent Exclusion Criteria: * Pre-existing long-term home oxygen therapy, or severe resting hypoxemia/ventilatory dysfunction (judged by the investigator to persistently affect safe rehabilitation) * Concurrent severe, uncontrolled cardiovascular disease (e.g., unstable angina, acute myocardial infarction or stroke within 3 months, NYHA class III-IV heart failure), severe hepatic insufficiency, or severe renal insufficiency * Other diseases or conditions that significantly affect motor function or compliance (e.g., severe neuromuscular/skeletal disorders, cognitive impairment, major psychiatric disorders) * Known or suspected contact allergy to medical adhesives or electrode materials used in the wearable devices, or skin conditions unsuitable for prolonged device attachment * Presence of implanted medical devices incompatible with the study wearable devices, or other contraindications as specified in the device instructions * Pregnancy or lactation, or women of childbearing potential who are unwilling to adopt effective contraceptive measures during the study period * Concurrent participation in another interventional clinical trial that may interfere with the outcomes of this study * Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation
References
Publications (0)
Data not yet available